RNS - re-cap23 Jan 2023 20:16
Evening all - a re - cap of todays RNS popped up on Ortex today
Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T 3rd Process Qualification Run Completed
"Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its third Process Qualification run of the end-to-end process for the manufacture of HEMO-CAR-T cells."
LONDON, UK /ACCESSWIREHemogenyx Pharmaceuticals plcThis PQ run is the third of minimum three identical manufacturing runs required for the submission of an Investigational New Drug ("IND") application to the US Food and Drug Administration ("FDA"). The IND is needed to obtain authorization from the FDA to commence Phase I clinical trials of HEMO-CAR-T. Following completion of all tests across all PQ runs, data will be compiled for inclusion in the IND submission pack.Enquiries:https://hemogenyx.comDr Vladislav Sandler, Chief Executive Officer
Evening throat nectar in every investors glass